Meningitis, Meningococcal Clinical Trial
Official title:
A Phase 2, Observer-blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Two Formulations of Investigational Meningococcal Groups ACYWX Conjugate Vaccine, Administered to Healthy Malian Children 12-16 Months of Age
Out of the 13 identified serogroups of Neisseria meningitidis (Nm) the six serogroups (A, B, C, W, Y and X) are responsible for majority of infections. Presently available vaccines effectively protect against A, B, C, W and Y serogroups; but no vaccine that is protective against serogroup X is available yet. Serum Institute of India Private Limited (SIIPL) has developed a conjugate vaccine against serogroups A, C, Y, W and X (NmCV-5). The first-in-human Phase 1 study was among 60 healthy adults in USA did not show no any safety issues. This phase 2 study is designed to evaluate safety and immunogenicity of the non-adjuvanted and adjuvanted formulations of NmCV-5 in healthy children 12-16 months of age, in comparison with the licensed quadrivalent meningococcal conjugate vaccine (Menactra®). Both vaccines will be administered in two dose schedule 3 months apart. among vaccine-naïve healthy subjects in Mali. Safety will be assessed by collecting solicited reactions till day 7 post each dose whereas adverse events will be collected throughout the study. Each subject will be followed up for 84 days post each vaccine dose. The vaccine immunogenicity will measured using a rabbit complement serum bactericidal activity assay (rSBA).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04689191 -
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
|
Phase 3 | |
| Recruiting |
NCT04689165 -
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
|
Phase 3 | |
| Completed |
NCT00780806 -
Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT03378258 -
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
|
||
| Completed |
NCT03205371 -
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers
|
Phase 3 | |
| Completed |
NCT01352793 -
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
|
Phase 3 | |
| Not yet recruiting |
NCT06113198 -
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
|
Phase 4 | |
| Completed |
NCT03493919 -
A Sourcing Study to Collect Human Blood Samples From Healthy Adults
|
Phase 4 | |
| Completed |
NCT00474526 -
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
|
Phase 3 | |
| Completed |
NCT00297687 -
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
|
Phase 1 | |
| Recruiting |
NCT04665791 -
A Human Controlled Infection Study With Neisseria Lactamica in Malian Adults
|
N/A | |
| Withdrawn |
NCT03431675 -
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
|
Phase 4 | |
| Recruiting |
NCT02878291 -
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
|
Phase 1 | |
| Completed |
NCT00314041 -
Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
|
Phase 2 | |
| Recruiting |
NCT04685850 -
Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura Fulminans
|
||
| Completed |
NCT03587207 -
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years
|
Phase 2 | |
| Completed |
NCT03824093 -
High and Low Resource Interventions to Promote HPV Vaccines
|
N/A | |
| Completed |
NCT04707391 -
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
|
Phase 3 | |
| Terminated |
NCT00798304 -
Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants
|
Phase 2 | |
| Recruiting |
NCT03682939 -
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population
|
Phase 4 |